RESUMEN
BACKGROUND: We sought to determine the pregnancy rate of U.S. military-dependent adolescents enrolled in the military healthcare system. METHODS: We examined the age and insurance status of dependent adolescents, ages 12 to 23, and determined the incidence of new pregnancies in the military healthcare system from 2006 to 2010 in San Antonio, Texas. Adolescents not enrolled or only recently enrolled in TRICARE Prime at the time of pregnancy were analyzed separately. A Cox-Proportional Hazards model was used to determine risk factors for pregnancy (relationship to sponsor, age, and contraceptive prescription). RESULTS: 444 pregnancies were diagnosed among the 12,417 eligible subjects. For adolescents with continuous enrollment in TRICARE Prime, the pregnancy rate was 9.67/1,000 woman-years at risk, much lower than the national average. Cox-Proportional Hazards analysis showed age group (15-19 years), and history of oral contraceptive prescription were associated with a higher pregnancy rate. 59% of pregnancies occurred in women not enrolled or only briefly enrolled in TRICARE Prime at the time of pregnancy. CONCLUSION: Dependent daughters enrolled in TRICARE Prime had a very low pregnancy rate. The majority of pregnancies occurred in adolescents not enrolled in TRICARE Prime at the time of pregnancy diagnosis, suggesting many adolescents sought health insurance after pregnancy was diagnosed.
Asunto(s)
Medicina Militar/organización & administración , Personal Militar , Índice de Embarazo/tendencias , Embarazo en Adolescencia/estadística & datos numéricos , Adolescente , Niño , Femenino , Estudios de Seguimiento , Humanos , Embarazo , Estudios Retrospectivos , Factores de Riesgo , Factores Socioeconómicos , Texas , Adulto JovenRESUMEN
Chronic hepatitis C virus (HCV) infection remains an important cause of liver disease in patients with end-stage renal disease (ESRD) and conversely, renal failure has a significant impact on morbidity and mortality throughout the natural history of chronic HCV and its treatment. With improved awareness within dialysis units of the potential for spread and the institution of preventative measures, the prevalence of HCV infection in the hemodialysis-dependent population has continued to decline since 1995. Use of HCV (+) donor kidneys is associated with an increase in the prevalence of liver disease, but when compared with continued hemodialysis, transplantation using these kidneys is associated with improved survival. Overall, survival in patients with chronic HCV infection appears to be better after renal transplantation when compared with maintenance hemodialysis, and transplant should be considered for these patients. Data support the use of interferon and the improved efficacy of pegylated interferon formulations for treatment of chronic HCV infection in ESRD patients, although tolerability continues to be troublesome. The newest and most promising data regarding the treatment of HCV in ESRD involve the combination of reduced dose ribavirin with interferon or pegylated interferon suggesting similar enhancements in sustained virologic response (SVR) as seen in non-ESRD patients, but caution is advised, as all studies to date used ribavirin plasma concentration monitoring in patient with ESRD. Finally, with regard to postrenal transplant treatment of HCV infection, there is no evidence to support treatment with interferon-based therapy and pretransplant treatment remains the best option whenever possible.
Asunto(s)
Hepatitis C Crónica/epidemiología , Fallo Renal Crónico/complicaciones , Antivirales/uso terapéutico , Hepatitis C Crónica/terapia , Hepatitis C Crónica/transmisión , Humanos , Fallo Renal Crónico/terapia , Trasplante de Riñón/efectos adversos , Diálisis RenalRESUMEN
Whether transplantation of deceased donor kidney allografts from donors with antibodies against hepatitis C virus (HCV) confers a survival advantage compared with remaining on the kidney transplant waiting list is not yet known. We studied 38,270 USRDS Medicare beneficiaries awaiting kidney transplantation who presented with end-stage renal disease from April 1, 1995 to July 31, 2000. Cox regression was used to compare the adjusted hazard ratios for death among recipients of kidneys from deceased donors, and donors with antibodies against hepatitis C (DHCV+), controlling for demographics and comorbidities. In comparison to staying on the waiting list, transplantation from DHCV+ was associated with improved survival among all patients (adjusted hazard ratio for death 0.76, 95% CI 0.60, 0.96). Of patients receiving DHCV+ kidneys, 52% were themselves hepatitis C antibody positive (HCV+), so outcomes associated with use of these grafts may have particular implications for HCV+ transplant candidates. Recommendations for use of DHCV+ kidneys may require analysis of data not currently collected from either dialysis or transplant patients. However, transplantation of DHCV+ kidneys is associated with improved patient survival compared to remaining wait-listed and dialysis dependent.
Asunto(s)
Hepatitis C/transmisión , Fallo Renal Crónico/cirugía , Trasplante de Riñón/estadística & datos numéricos , Donantes de Tejidos/estadística & datos numéricos , Anciano , Bases de Datos Factuales , Humanos , Trasplante de Riñón/mortalidad , Medicare , Análisis de Supervivencia , Donantes de Tejidos/provisión & distribución , Resultado del Tratamiento , Estados Unidos , Listas de EsperaRESUMEN
Complications associated with use of donor hepatitis C-positive kidneys (DHCV+) have been attributed primarily to posttransplantation liver disease (as a result of hepatitis C disease). The role of posttransplantation diabetes has not been explored in this setting. With the use of the United States Renal Data System database, 28,942 Medicare KT recipients were studied from January 1, 1996, through July 31, 2000. Cox proportional hazards regression models were used to calculate adjusted hazard ratios (AHR) for the association of sero-pairs for HCV (D+/R-, D+/R+, D-/R+ and D-/R-) with Medicare claims for de novo posttransplantation HCV and posttransplantation diabetes. The peak risk for posttransplantation HCV was in the first 6 mo after transplantation. The incidence of posttransplantation HCV after transplantation was 9.1% in D+/R-, 6.3% in D+/R+, 2.4% in D-/R+, and 0.2% in D-/R-. The incidence of posttransplantation diabetes after transplantation also peaked early and was 43.8% in D+/R-, 46.6% in D+/R+, 32.3% in D-/R+, and 25.4% in D-/R-. Associations for both complications were significant in adjusted analysis (Cox regression). Both posttransplantation HCV (AHR, 3.36; 95% confidence interval, 2.44 to 4.61) and posttransplantation diabetes (AHR, 1.81; 95% confidence interval, 1.54 to 2.11) were independently associated with an increased risk of death, but posttransplantation diabetes accounted for more years of life lost, particularly among recipients of DHCV+ kidneys. Posttransplantation diabetes may contribute substantially to the increased risk of death associated with use of DHCV+ kidneys and accounts for more years of life lost than posttransplantation HCV. Because HCV infection acquired after transplantation is so difficult to treat, methods that have been shown to reduce viral transmission warrant renewed attention.
Asunto(s)
Diabetes Mellitus Tipo 2/mortalidad , Hepatitis C/mortalidad , Fallo Renal Crónico/mortalidad , Trasplante de Riñón/mortalidad , Adulto , Femenino , Estudios de Seguimiento , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Factores de Riesgo , Donantes de Tejidos/estadística & datos numéricosRESUMEN
Severity of heart disease of almost all types, as well as mortality risk associated with heart disease, increases in step with severity of kidney disease, although not necessarily in a linear fashion. Heart failure is more common and just as lethal as ischemic heart disease in patients with severe chronic kidney disease (CKD). The incidence of nonfatal heart disease in dialysis and transplant populations has now been described in detail. Although standard risk factors for heart disease that are more common among patients with CKD than in the general population do not adequately explain the greatly increased risk of heart disease in patients with severe CKD, neither do as yet identified "nontraditional" risk factors. However, in addition to the factors not common in the general population, such as anemia, hyperphosphatemia, and markers of systemic inflammation, patients with CKD in the modern era may also exhibit excessive thrombotic tendencies. Screening for heart disease in this population relies mainly on dobutamine stress echocardiography or nuclear scintigraphy. The role of electron beam CT (EBCT) scanning is currently controversial. The indications for coronary angiography are the same for patients with CKD as for the general population, but patients with CKD are at greatly increased risk for contrast-associated nephropathy, the least controversial preventive therapy, which consists of isotonic saline and N-acetylcysteine. Finally, patients with CKD do not currently receive adequate medical therapy for prevention and treatment of heart disease.
Asunto(s)
Enfermedades Cardiovasculares/etiología , Fallo Renal Crónico/complicaciones , Enfermedades Cardiovasculares/diagnóstico , Enfermedades Cardiovasculares/prevención & control , Enfermedades Cardiovasculares/terapia , Enfermedad Coronaria/etiología , Insuficiencia Cardíaca/etiología , Humanos , Fallo Renal Crónico/fisiopatología , Fallo Renal Crónico/terapia , Trasplante de Riñón , Diálisis Renal , Factores de RiesgoRESUMEN
Analysis of the USRDS kidney transplant registry disclosed that use of hepatitis C virus-positive donor (DHCV+) kidneys was an independent risk factor for patient death after kidney transplantation when compared to use of DHCV- kidneys, and that death in recipients of DCHV+ kidneys occurred earlier than previously reported. This increased risk of death was delayed for about 2 years, suggesting the development of an intermediate complication that resulted in a later increased risk of death. While liver disease early after transplant in these patients was rare, new-onset diabetes mellitus occurred early and commonly, suggesting this complication as a prominent mediator of mortality associated with transplantation with DHCV+ kidneys. Identification of new-onset diabetes mellitus may represent a new target of opportunity to improve outcomes associated with use of DHCV+ kidneys. Even under the current circumstances, use of DHCV+ kidneys was also independently associated with a survival experience that, although less favorable than associated with transplantation of DHCV- kidneys, was significantly better than remaining on the kidney transplant waiting list. Whether this survival advantage applies to all relevant subgroups could not be assessed and warrants further study. Our analyses suggest opportunities to improve survival and reduce morbidity after use of DHCV+ kidneys.
Asunto(s)
Hepatitis C/etiología , Trasplante de Riñón/estadística & datos numéricos , Bases de Datos Factuales , Diabetes Mellitus/etiología , Supervivencia de Injerto , Hepatitis C/transmisión , Hepatitis C/virología , Humanos , Trasplante de Riñón/efectos adversos , Trasplante de Riñón/mortalidad , Tasa de Supervivencia , Donantes de Tejidos , Obtención de Tejidos y Órganos/estadística & datos numéricos , Resultado del Tratamiento , Estados Unidos/epidemiología , Listas de EsperaRESUMEN
Kidneys from donors who are positive for hepatitis C virus (DHCV+) have recently been identified as an independent risk factor for mortality after renal transplantation. However, it has not been determined whether risk persists after adjustment for baseline cardiac comorbidity or applies in the era of modern immunosuppression. Therefore, a historical cohort study was conducted of US adult cadaveric renal transplant recipients from January 1, 1996, to May 31, 2001; followed until October 31, 2001. A total of 36,956 patients had valid donor and recipient HCV serology. Cox regression analysis was used to model adjusted hazard ratios for mortality and graft loss, respectively, adjusted for other factors, including comorbid conditions from Center for Medicare and Medicaid Studies Form 2728 and previous dialysis access-related complications. It was found that DHCV+ was independently associated with an increased risk of mortality (adjusted hazard ratio, 2.12, 95% confidence interval, 1.72 to 2.87; P < 0.001), primarily as a result of infection. Mycophenolate mofetil was associated with improved survival in DHCV+ patients, primarily related to fewer infectious deaths. Adjusted analyses limited to recipients who were HCV+, HCV negative, or age 65 and over, or by use of mycophenolate mofetil confirmed that DHCV+ was independently associated with mortality in each subgroup. It is concluded that DHCV+ is independently associated with an increased risk of mortality after renal transplantation adjusted for baseline comorbid conditions in all subgroups. Recipients of DHCV+ organs should be considered at high risk for excessive immunosuppression.
Asunto(s)
Supervivencia de Injerto , Anticuerpos contra la Hepatitis C/sangre , Fallo Renal Crónico/sangre , Fallo Renal Crónico/mortalidad , Trasplante de Riñón , Donantes de Tejidos , Adolescente , Adulto , Estudios de Cohortes , Humanos , Fallo Renal Crónico/cirugía , Persona de Mediana Edad , Estudios Retrospectivos , Tasa de Supervivencia , Resultado del Tratamiento , Estados Unidos/epidemiologíaRESUMEN
BACKGROUND: The national incidence of and factors associated with total hip arthroplasty (THA) in chronic dialysis patients has never been reported. METHODS: We therefore performed an historical cohort study of 375,857 chronic dialysis patients listed in the 2000 United States Renal Data System between 1 April 1995 and 31 December 1999 and followed-up until 14 May 2000. Primary outcomes were associations with hospitalizations for a primary discharge code of THA (ICD9 procedure code 81.51x) after initiation of dialysis. RESULTS: Dialysis patients had a cumulative incidence of THA of 35 episodes/10,000 person-years, compared to 5.3/10,000 in the general population. The leading indication for THA was osteoarthritis of the hip and pelvis (58% of cases). However, the strongest risk factor for THA in dialysis patients was end-stage renal disease (ESRD) due to systemic lupus erythematosus (SLE, adjusted rate ratio (ARR), 6.80, 95% CI 4.62-10.03, in whom avascular necrosis of the hip was the most common indication, 68.4%). The database did not include information on use of corticosteroids. Diabetic recipients were significantly less likely to receive THA, as were males, and African Americans. Mortality after THA was 0.25% at thirty days and 30% at three years, not significantly different from the expected mortality of dialysis, adjusted for comorbidity. CONCLUSIONS: The most common indication for THA in dialysis patients is osteoarthritis of the hip, similar to the general population. Patients with SLE are more likely to receive THA which is well tolerated and not associated with increased mortality in this population, perhaps reflecting selection bias due to appropriate screening for this elective procedure.
Asunto(s)
Artroplastia de Reemplazo de Cadera/estadística & datos numéricos , Fallo Renal Crónico/terapia , Diálisis Renal/estadística & datos numéricos , Anciano , Artroplastia de Reemplazo de Cadera/métodos , Estudios de Cohortes , Intervalos de Confianza , Femenino , Humanos , Incidencia , Fallo Renal Crónico/epidemiología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/cirugía , Masculino , Persona de Mediana Edad , Oportunidad Relativa , Osteoartritis de la Cadera/epidemiología , Osteoartritis de la Cadera/cirugía , Probabilidad , Pronóstico , Modelos de Riesgos Proporcionales , Sistema de Registros , Factores de Riesgo , Tasa de Supervivencia , Resultado del Tratamiento , Estados Unidos/epidemiologíaRESUMEN
The national incidence of and factors associated with total hip arthroplasty in renal transplant recipients has not been reported. We conducted an historical cohort study of 42096 renal transplant recipients in the United States between 1 July 1994 and 30 June 1998. Primary outcomes were associations with hospitalizations for a primary discharge code of total hip arthroplasty (ICD9 procedure code 81.51x) within 3 years after renal transplant using Cox regression. Renal transplant recipients had a cumulative incidence of total hip arthroplasty of 5.1 episodes/1000 person-years, which is 5-8 times higher than reported in the general population. Avascular necrosis of the hip was the most frequent primary diagnosis associated with total hip arthroplasty in this population (72% of cases). Repeat surgeries were performed in 27% of patients with avascular necrosis, vs. 15% with other diagnoses. Total hip arthroplasty was more frequent in transplant recipients who were older, African American, or who experienced allograft rejection. Mortality after total hip arthroplasty was 0.21% at 30 days and 15% at 3 years, similar to the mortality of all transplant recipients. The most common indication for total hip arthroplasty after renal transplant is avascular necrosis of the hip, in contrast to the general population. Although repeat surgeries are common, total hip arthroplasty is well tolerated and is not associated with increased mortality in this population.
Asunto(s)
Artroplastia de Reemplazo de Cadera/estadística & datos numéricos , Hospitalización/estadística & datos numéricos , Complicaciones Posoperatorias/epidemiología , Adulto , Estudios de Cohortes , Nefropatías Diabéticas/epidemiología , Nefropatías Diabéticas/cirugía , Femenino , Humanos , Incidencia , Fallo Renal Crónico/clasificación , Fallo Renal Crónico/cirugía , Trasplante de Riñón , Masculino , Complicaciones Posoperatorias/mortalidad , Terapia de Reemplazo Renal/estadística & datos numéricos , Factores de Riesgo , Tasa de Supervivencia , Factores de Tiempo , Resultado del Tratamiento , Estados Unidos/epidemiologíaRESUMEN
The impact of hepatitis C virus-positive donor kidneys on patient survival has not been analyzed in a national study. This study analyzed 20,111 adult (age, > or =16 yr) recipients having solitary cadaveric kidney transplants from adult donors with valid donor hepatitis C serologies from July 1, 1994, to June 30, 1998, in an historical cohort study (the 2000 United States Kidney Data System) of patient survival. Analysis was by the Cox proportional hazards models, which corrected for characteristics thought to affect outcomes. Of 484 kidneys positive for hepatitis C virus serology, 165 (34%) were given to recipients with confirmed negative hepatitis C serologies. Unadjusted 3-yr patient survival was 93% in all recipients of donor hepatitis C-negative kidneys versus 85% in all recipients of donor hepatitis C-positive kidneys (P = 0.01). Among hepatitis C-positive recipients, those who received hepatitis C-positive kidneys had worse survival than recipients of hepatitis C-negative kidneys. Among elderly hepatitis C-negative recipients, those who received hepatitis C-positive kidneys also had worse survival; in fact, all recipients of donor hepatitis C-positive kidneys had increased risk of mortality (P = 0.028). There were no significant interactions between donor hepatitis C positivity and either recipient hepatitis C positivity or older recipient age. The use of hepatitis C-positive kidneys in recipients who were hepatitis C-negative was fairly common and contrary to some current recommendations. Recipients of donor hepatitis C-positive kidneys were at independently increased risk of mortality, with no evidence that any subgroups were less affected.
Asunto(s)
Supervivencia de Injerto , Hepatitis C/diagnóstico , Trasplante de Riñón , Pruebas Serológicas , Donantes de Tejidos , Adulto , Cadáver , Estudios de Cohortes , Humanos , Trasplante de Riñón/mortalidad , Persona de Mediana Edad , Estudios Retrospectivos , Análisis de SupervivenciaRESUMEN
The impact of graft loss on acute coronary syndromes (ACS) after renal transplantation has not been studied in a national population. It was hypothesized that ACS might be more frequent after graft loss, as many of the benefits of a functioning allograft on metabolism and volume regulation would be lost. Data from the 2000 United States Renal Data System (USRDS) was used to conduct an historical cohort study of ACS in 14,237 patients who received renal transplants between April 1, 1995, and June 30, 1998, (followed until April 28, 2000) with valid information from CMS Form 2728, excluding patients with hospitalized ACS before renal transplant. Cox nonproportional regression models were used to calculate the time-dependent adjusted hazard ratio (AHR) of graft loss (censored for death) for time-to-first hospitalization for ACS (International Classification of Diseases 9th Modification Diagnosis Codes [ICD9] code 410.x or 411.x) occurring after transplant. The incidence of ACS was 12.1 per 1000 patient-years (PY) in patients after graft loss versus 6.5 per 1000 PY after transplantation (excluding patients with graft loss). As a time-dependent variable, graft loss had an AHR of 2.54 (95% confidence interval, 1.09 to 5.96; P = 0.031 by Cox regression). Other risk factors associated with ACS included diabetes, older recipient, and male recipient. Allograft rejection was NS. Renal transplant recipients share some of the risk factors for ACS with the general population. In addition, graft loss was identified as a unique risk factor for ACS in this population.